Inhibitors
Cat.No. | Name | Information |
---|---|---|
M2050 | GSK2636771 | GSK2636771 is a potent, orally available and specific PI3K p110β (PI3K beta, PI3Kβ) inhibitor. |
M1925 | LY294002 | LY294002 is a highly selective PI3K inhibitor with IC50 values of 0.31, 0.73, 1.06 and 6.60 μM for PI3Kβ, PI3Kα, PI3Kδ and PI3Kγ respectively. |
M2296 | 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM, respectively. |
M1715 | GDC-0941 (Pictilisib) | GDC-0941 is a selective and potent inhibitor of Class I PI3K, p110a IC50=0.003uM, U87MG IC50=0.95μM. |
M1984 | PF-04691502 | PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively. |
M21296 | PF-06843195 | PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts.The Ki of PF-06843195 acting on PI3Kα and PI3Kδ is less than 0.018 nM and 0.28 nM, respectively.PF-06843195 has a significant inhibitory effect on PI3K/mTOR signaling pathway and had a long-lasting anti-tumor effect. |
M21171 | AZD8154 | AZD8154 is a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory diseases. |
M21093 | NVP-CLR457 | NVP-CLR457 is an orally administered, non-CNS-penetrating, pan-IA-like phosphoinositide 3-kinase (PI3K) inhibitor.NVP-CLR457 shows a significant dose-dependent PK / PD / efficacy relationship.NVP-CLR457 has antitumor activity. |
M20796 | ME-401 | ME-401 (PWT-143, P110δ-IN-1) is an oral, potent and selective inhibitor of Phosphatidylinositol 3-Kinase (PI3K) P110δ with IC50 of 0.6 nM in cellular assay. |
M20759 | 3-Hydroxyanthranilic acid | 3-Hydroxyanthranilic Acid (3-HAA, 3-HANA), a tryptophan metabolite, has an immunomodulatory effect that may result from inhibition of PI3K/Akt/mTOR and NF-κB activity, thereby decreasing the production of pro-inflammatory mediators. |
M20632 | Selective PI3Kδ Inhibitor 1 (compound 7n) | Selective PI3Kδ Inhibitor 1 (compound 7n) is an inhibitor of PI3Kδ with an IC50 of 0.9 nM and >1000-fold selectivity against other class I PI3K isoforms [PI3K α/γ/β=3670/1460/21300 nM]. |
M20610 | AMG319 | AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2. |
M20589 | KDU691 | KDU691 is a Plasmodium PI4K -specific inhibitor with IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively. |
M20587 | BQR695 | BQR695 is a quinoxaline that displays sub-micromolar potency against human PI4KIIIβ (IC50~90 nM). |
M20353 | WAY-278705 | WAY-278705 is a phosphoinositide 3-kinase (PI3 kinase) modulator. |
M20344 | WAY-299017 | WAY-299017 is a selective inhibitor of mutant H1047R phosphoinositide- 3-kinase (PI3Ka). |
M20331 | WAY-232261 | WAY-232261 is a PI3 kinase inhibitor. |
M20260 | WAY-647361 | WAY-647361 is a PI3 kinase inhibitor |
M20185 | WAY-601035 | WAY-601035 is a PI3Kγ inhibitor |
M20184 | WAY-601017 | WAY-601017 is a phosphatidylinositol 3-kinase inhibitor |
M20049 | WAY-272324 | WAY-272324 is a Phosphoinositide 3-Kinase γ inhibitor. |
M20026 | WAY-107407 | WAY-107407 altering the lifespan of a eukaryotic organism |
M14860 | PI4KIIIbeta-IN-9 | PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively. |
M14859 | Vps34-IN-2 | Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively. |
M14858 | Umbralisib hydrochloride | Umbralisib hydrochloride (TGR-1202 hydrochloride) is a novel PI3Kδ inhibitor, with IC50 and EC50 of 22.2 nM and 24.3 nM, respectively; Umbralisib hydrochloride (TGR-1202 hydrochloride) is also active against CK1ε, with an EC50 value of 6.0 μM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.